相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Probing In Silico the Benzimidazole Privileged Scaffold for the Development of Drug-like Anti-RSV Agents
Elena Cichero et al.
PHARMACEUTICALS (2021)
Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays
Alice Parodi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
New Insights into the Binding Features of F508del CFTR Potentiators: A Molecular Docking, Pharmacophore Mapping and QSAR Analysis Approach
Giada Righetti et al.
PHARMACEUTICALS (2020)
Novel 1-Amidino-4-Phenylpiperazines as Potent Agonists at Human TAAR1 Receptor: Rational Design, Synthesis, Biological Evaluation and Molecular Docking Studies
Valeria Francesconi et al.
PHARMACEUTICALS (2020)
Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors
Giada Righetti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809
Jake E. Doiron et al.
CHEMISTRY-A EUROPEAN JOURNAL (2019)
STRUCTURE, GATING, AND REGULATION OF THE CFTR ANION CHANNEL
Laszlo Csanady et al.
PHYSIOLOGICAL REVIEWS (2019)
Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools
Nara Liessi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis
Xueqing Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Structure-guided combination therapy to potently improve the function of mutant CFTRs
Guido Veit et al.
NATURE MEDICINE (2018)
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Dominic Keating et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
J. C. Davies et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Molecular structure of the ATP-bound, phosphorylated human CFTR
Zhe Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface
Rhea P. Hudson et al.
MOLECULAR PHARMACOLOGY (2017)
New treatments targeting the basic defects in cystic fibrosis
Isabelle Fajac et al.
PRESSE MEDICALE (2017)
From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations
Gudio Veit et al.
MOLECULAR BIOLOGY OF THE CELL (2016)
Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis
Emanuela Pesce et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Diaryl-Substituted (Dihydro)pyrrolo[3,2,1-hi]indoles, a Class of Potent COX-2 Inhibitors with Tricyclic Core Structure
Markus Laube et al.
JOURNAL OF ORGANIC CHEMISTRY (2015)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
C. E. Wainwright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cystic fibrosis genetics: from molecular understanding to clinical application
Garry R. Cutting
NATURE REVIEWS GENETICS (2015)
Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl) amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors
Yonghui Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
VX-809 and Related Corrector Compounds Exhibit Secondary Activity Stabilizing Active F508del-CFTR after Its Partial Rescue to the Cell Surface
Paul D. W. Eckford et al.
CHEMISTRY & BIOLOGY (2014)
Docking assay of small molecule antivirals to p7 of HCV
Leon Bichmann et al.
COMPUTATIONAL BIOLOGY AND CHEMISTRY (2014)
Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression
Guido Veit et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Revertants, Low Temperature, and Correctors Reveal the Mechanism of F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction
Carlos M. Farinha et al.
CHEMISTRY & BIOLOGY (2013)
Rescuing Mutant CFTR: A Multi-task Approach to a Better Outcome in Treating Cystic Fibrosis
Margarida D. Amaral et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Mechanism-based corrector combination restores ΔF508-CFTR folding and function
Tsukasa Okiyoneda et al.
NATURE CHEMICAL BIOLOGY (2013)
Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle
Kang-Yang Jih et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Substantial improvements in large-scale redocking and screening using the novel HYDE scoring function
Nadine Schneider et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2012)
Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia
Paolo Scudieri et al.
JOURNAL OF PHYSIOLOGY-LONDON (2012)
CFTR: folding, misfolding and correcting the ΔF508 conformational defect
Gergely L. Lukacs et al.
TRENDS IN MOLECULAR MEDICINE (2012)
Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis
Zhi-wei Cai et al.
ACTA PHARMACOLOGICA SINICA (2011)
Dual Activity of Aminoarylthiazoles on the Trafficking and Gating Defects of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Caused by Cystic Fibrosis Mutations
Nicoletta Pedemonte et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Towards an integrated description of hydrogen bonding and dehydration: Decreasing false positives in virtual screening with the HYDE scoring function
Ingo Reulecke et al.
CHEMMEDCHEM (2008)
Adapting proteostasis for disease intervention
William E. Balch et al.
SCIENCE (2008)
Domain interdependence in the biosynthetic assembly of CFTR
Liying Cui et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Cystic fibrosis: A worldwide analysis of CFTR mutations - Correlation with incidence data and application to screening
JL Bobadilla et al.
HUMAN MUTATION (2002)
分享论文
